Oda Y, Kumagai Y, Kanai M, et al. 12-month persistence of immune responses to self-amplifying mRNA COVID-19 vaccines: ARCT-154 versus BNT162b2 vaccine. Lancet Infect Dis 2024; published online Oct 7. https://doi.org/10.1016/S1473-3099(24)00615-7—In this Correspondence, the figure labels have been corrected with ARCT-154 labelled red and BNT162b2 as blue. These corrections have been made to the online version as of Oct 18, 2024.

中文翻译：

---

对柳叶刀感染疾病 2024 的更正;10 月 7 日在线发布。https://doi.org/10.1016/S1473-3099（24）00615-7


Oda Y、Kumagai Y、Kanai M 等人对自扩增 mRNA COVID-19 疫苗的免疫反应持续 12 个月：ARCT-154 与 BNT162b2 疫苗的比较。柳叶刀感染疾病 2024;10 月 7 日在线发布。https://doi.org/10.1016/S1473-3099（24）00615-7—在本通信中，图形标签已更正，ARCT-154 标记为红色，BNT162b2 标记为蓝色。这些更正已对 2024 年 10 月 18 日的在线版本进行了修改。